NASDAQ:ASMB

Assembly Biosciences Competitors

$4.10
-0.18 (-4.21 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.07
Now: $4.10
$4.31
50-Day Range
$4.25
MA: $4.64
$5.17
52-Week Range
$4.07
Now: $4.10
$27.84
Volume686,367 shs
Average Volume1.23 million shs
Market Capitalization$164.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61

Competitors

Assembly Biosciences (NASDAQ:ASMB) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying ASMB stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Assembly Biosciences, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Assembly Biosciences (NASDAQ:ASMB) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Assembly Biosciences-60.14%-18.75%-15.89%
Johnson & Johnson21.01%34.64%13.40%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Assembly Biosciences02402.67
Johnson & Johnson031102.79

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Johnson & Johnson has a consensus target price of $182.6154, suggesting a potential upside of 12.25%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Johnson & Johnson.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10
Johnson & Johnson$82.06 billion5.22$15.12 billion$8.6818.74

Johnson & Johnson has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Assembly Biosciences on 10 of the 14 factors compared between the two stocks.

Assembly Biosciences (NASDAQ:ASMB) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Assembly Biosciences-60.14%-18.75%-15.89%
Pfizer17.85%24.88%9.32%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Assembly Biosciences02402.67
Pfizer010302.23

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Pfizer has a consensus target price of $38.5714, suggesting a potential downside of 0.92%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Pfizer.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Pfizer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10
Pfizer$51.75 billion4.20$16.27 billion$2.9513.20

Pfizer has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Assembly Biosciences on 8 of the 14 factors compared between the two stocks.

Assembly Biosciences (NASDAQ:ASMB) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Assembly Biosciences-60.14%-18.75%-15.89%
Merck & Co., Inc.24.33%53.83%16.83%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Assembly Biosciences02402.67
Merck & Co., Inc.021102.85

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Merck & Co., Inc. has a consensus target price of $96.2727, suggesting a potential upside of 23.97%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Merck & Co., Inc..

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Merck & Co., Inc.'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10
Merck & Co., Inc.$46.84 billion4.20$9.84 billion$5.1914.96

Merck & Co., Inc. has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Assembly Biosciences on 9 of the 14 factors compared between the two stocks.

Assembly Biosciences (NASDAQ:ASMB) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Assembly Biosciences and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Assembly Biosciences-60.14%-18.75%-15.89%
AbbVie18.16%439.24%13.22%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Assembly Biosciences02402.67
AbbVie121302.75

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. AbbVie has a consensus target price of $115.75, suggesting a potential upside of 6.57%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than AbbVie.

Earnings & Valuation

This table compares Assembly Biosciences and AbbVie's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10
AbbVie$33.27 billion5.76$7.88 billion$8.9412.15

AbbVie has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Summary

AbbVie beats Assembly Biosciences on 10 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Eli Lilly and and Assembly Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Assembly Biosciences-60.14%-18.75%-15.89%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Assembly Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
Assembly Biosciences02402.67

Eli Lilly and presently has a consensus price target of $196.40, suggesting a potential upside of 3.56%. Assembly Biosciences has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Assembly Biosciences' higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Eli Lilly and.

Valuation and Earnings

This table compares Eli Lilly and and Assembly Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion8.15$8.32 billion$6.0431.40
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10

Eli Lilly and has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 92.2% of Assembly Biosciences shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 7.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Eli Lilly and has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Summary

Eli Lilly and beats Assembly Biosciences on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Bristol-Myers Squibb and Assembly Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Assembly Biosciences-60.14%-18.75%-15.89%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bristol-Myers Squibb and Assembly Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb021312.94
Assembly Biosciences02402.67

Bristol-Myers Squibb presently has a consensus price target of $74.60, suggesting a potential upside of 13.72%. Assembly Biosciences has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Assembly Biosciences' higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Bristol-Myers Squibb.

Valuation and Earnings

This table compares Bristol-Myers Squibb and Assembly Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.61$3.44 billion$4.6913.99
Assembly Biosciences$15.96 million10.29$-97,630,000.00($3.72)-1.10

Bristol-Myers Squibb has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 92.2% of Assembly Biosciences shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 7.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Assembly Biosciences on 10 of the 15 factors compared between the two stocks.


Assembly Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.69-0.3%$428.32 billion$82.06 billion25.58
Pfizer logo
PFE
Pfizer
2.3$38.93-0.9%$217.14 billion$51.75 billion25.12Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.66-0.2%$196.51 billion$46.84 billion17.18Increase in Short Interest
AbbVie logo
ABBV
AbbVie
2.8$108.61-0.6%$191.68 billion$33.27 billion22.96Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.64-0.2%$181.86 billion$22.32 billion30.99Upcoming Earnings
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.60-0.2%$146.55 billion$26.15 billion-596.31Analyst Upgrade
Zoetis logo
ZTS
Zoetis
2.2$168.10-0.3%$79.85 billion$6.26 billion49.88Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.77-0.2%$25.36 billionN/A0.00Dividend Announcement
Increase in Short Interest
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$90.26-3.3%$20.22 billion$1.30 billion24.66
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$167.16-1.0%$9.42 billion$2.16 billion52.73
Perrigo logo
PRGO
Perrigo
2.3$41.70-0.2%$5.57 billion$4.84 billion-694.88Dividend Announcement
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.80-1.1%$3.43 billion$114.62 million-7.58
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.51-0.7%$2.79 billion$421.03 million22.36
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.90-0.6%$2.69 billion$306.49 million25.73
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$30.95-2.4%$1.64 billion$392.76 million12.84Analyst Upgrade
Gap Up
Endo International logo
ENDP
Endo International
1.5$5.89-6.3%$1.36 billion$2.91 billion-8.66News Coverage
Gap Up
Omeros logo
OMER
Omeros
1.4$18.08-1.6%$1.12 billion$111.81 million-7.60News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$18.92-0.4%$1.05 billion$3.65 million-1.99
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.93-1.0%$371.86 million$16.54 million-3.22
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.34-2.4%$336.88 million$111.39 million23.86News Coverage
Lannett logo
LCI
Lannett
2.0$4.93-3.4%$204.11 million$545.74 million-6.85
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.99-0.0%$44.61 million$47.53 million-13.59
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.